Navigation Links
ULURU Inc. Extends the European Altrazeal® License to Include the Middle East and Africa
Date:1/17/2012

ADDISON, Texas, Jan. 17, 2012 /PRNewswire/ --ULURU Inc. (NYSE AMEX: ULU), announced today that it has extended the previously announced European license for Altrazeal® to include the Middle East and North Africa.

Commenting on the extension of the territory, Helmut Kerschbaumer Chairman of Melmed Holdings AG, stated, "This is a territory where Melmed Holdings AG has experience marketing to the various sectors in these markets. We have an extensive network of marketing partners and contacts to penetrate this market. In addition, there are various European organizations that provide humanitarian aid to numerous markets that can be accessed to quickly establish a market presence."

Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressings. Altrazeal® competes in the advanced wound dressing market which worldwide is estimated to be $6.5 billion growing annually at 13%. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous ulcers and geriatric wounds.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.uluruinc.com.  For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended.  These statements are subject to numerous risks and uncertainties, including but not limited to our belief that Altrazeal® will be a major competitor in the wound care market, the ability to quickly establish a market presence, the cost effectiveness and cost savings of Altrazeal® in healing chronic wounds, and Altrazeal®'s clinical and economic advantage and to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Extends the European Altrazeal® License to Include Australia and New Zealand
2. ULURU Inc. Receives Notice From NYSE Amex Regarding Continued Listing Standards
3. ULURU Inc. Reports Third Quarter 2011 Financial Results
4. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2011 and to Provide a Business Update
5. ULURU Inc. Announces Altrazeal® Agreement for the European Market
6. ULURU Inc. Receives NYSE Amex Notice of Non-Compliance with Continued Listing Standards
7. ULURU Inc. Enters Into Strategic Financings of Up to $1.6 Million at a Premium to Current Share Price
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Second Quarter Ended June 20, 2011 and to Provide a Business Update
9. ULURU Inc. Announces Reverse Stock Split
10. ULURU Inc. Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor
11. ULURU Inc. Announces Voting Results of Reconvened Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... in Drug Discovery and Diagnostics, 2017 - 2035" report to ... The ... current landscape and future outlook of the growing market of deep ... data revolution, deep learning algorithms have emerged as a novel solution ...
(Date:3/24/2017)... 24, 2017 Today Stock-Callers.com have issued ... are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards ... SSH ). These companies are part of the Healthcare ... Thursday, March 23 rd , 2017, with the NYSE Health ... health care companies in the S&P 500 were down about ...
(Date:3/24/2017)... INDIANAPOLIS , March 24, 2017  Eli ... today announced plans to invest $850 million in ... span facilities across its U.S. enterprise, including research ... The investments are being driven by demand for ... of potential medicines in development targeting cancer, pain, ...
Breaking Medicine Technology:
(Date:3/25/2017)... ... ... Swissray is pleased to announce the release of the ELITE DXA, a new bone ... scan window, which is more than double that of existing bone densitometers. Historically, subjects ... an accurate total body bone density or body composition study. The ELITE DXA ...
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT ... by providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned ... education developed in cooperation with the American College of Surgeons to promote critical ...
(Date:3/24/2017)... NY (PRWEB) , ... March 24, 2017 , ... ... scale; from third world countries to hospitals in the United States, it’s a ... conversation on the current obstacles facing infection prevention and offers strategies for the ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association (RBMA) ... awards, now in their 12th year, are among the most prestigious in radiology marketing ... the awards were retooled to recognize achievements in both large budget (over $5,000) and ...
(Date:3/24/2017)... TX (PRWEB) , ... March 24, 2017 , ... ... clinic which can be found at 9618 Huebner Road. The clinic is the group’s ... OCS, Clinic Director, and Dr. Ali Higgins, PT, will provide care from the clinic, ...
Breaking Medicine News(10 mins):